Business Context and Reporting Period
This Form 8-K Current Report was filed by Tempest Therapeutics, Inc. on September 7, 2023, covering events occurring on September 2, 2023. The filing addresses significant changes in executive leadership and board composition.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation arrangements:
- Consulting Retainer: $8,000 for the period between September 15, 2023, and October 15, 2023.
- Hourly Rate: $500 per hour for services rendered after October 15, 2023.
Material Changes
The primary material change reported is the departure of Tom Dubensky, Ph.D., who resigned as President and member of the Board of Directors effective September 2, 2023. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Leadership Transition: Stephen Brady, the current Chief Executive Officer, was appointed as President and CEO effective September 15, 2023 (the Separation Date).
- Role Change: Dr. Dubensky will transition to an advisor and consultant role to assist with the transition of responsibilities.
Outlook, Risks, and Unusual Items
The filing outlines a separation and consulting agreement expected to be entered into with Dr. Dubensky. Under this agreement, the Company expects to retain his services until at least December 15, 2023. No specific risks, contingencies, or unusual items beyond the leadership transition were disclosed in this report. The full text of the separation agreement is expected to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
Investor Verification Checklist
- Verify the execution of the separation and consulting agreement with Dr. Dubensky in the upcoming Form 10-Q filing.
- Confirm the effective date of Stephen Brady's appointment as President and CEO (September 15, 2023).
- Monitor future filings for any additional financial impact related to the consulting arrangement.